Shilpa Medicare enters Phase I Clinical Trial for its new biological entity

01 Nov 2021 Evaluate

Shilpa Medicare (SML), via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has been permitted to conduct a Phase I human clinical study on its flagship novel product - recombinant Human Albumin (NavAlbumin), by the Central Drugs Standard Control Organisation (CDSCO).

The product, is a synthetically developed product as compared to the current process of drawing the same from blood plasma and is backed by granted global patent. It is designated a 'New Biological Entity' and is amongst the first indigenously developed novel molecules entering clinical studies - a significant milestone for the company and potentially large impact for the nation. The Company continues to strengthen its patent protection around the product to ring fence it from any potential competition.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

319.85 -0.65 (-0.20%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×